Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Fabio Cataldi, Michelle Hinz et al.|Gut|2015Cited by 157
P516 Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody studyWalter Reinisch, Fabio Cataldi, Julián Panés et al.|Journal of Crohn s and Colitis|2014Cited by 4
Mo1207 Discrepancy Between Fecal Biomarkers and Their Intestinal Gene Expression in Ulcerative Colitis: Results From an Anti-IL-13 Antibody StudyWalter Reinisch, Fabio Cataldi, Michelle Hinz et al.|Gastroenterology|2014Cited by 1